RN-1665 is an orally active TRPV4 antagonist with excellent selectivity over related TRP receptors (such as TRPV1, TRPV3, and TRPM8); it can be used as a TRPV4 probe for target-focused screening, with IC50 values of 0.26 μM and 0.39 μM against human (hTRPV4) and rat (rTRPV4) TRPV4, respectively.